These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
305 related articles for article (PubMed ID: 32973149)
1. Abiraterone acetate preferentially enriches for the gut commensal Akkermansia muciniphila in castrate-resistant prostate cancer patients. Daisley BA; Chanyi RM; Abdur-Rashid K; Al KF; Gibbons S; Chmiel JA; Wilcox H; Reid G; Anderson A; Dewar M; Nair SM; Chin J; Burton JP Nat Commun; 2020 Sep; 11(1):4822. PubMed ID: 32973149 [TBL] [Abstract][Full Text] [Related]
2. Abiraterone acetate in the treatment of prostate cancer. Thakur A; Roy A; Ghosh A; Chhabra M; Banerjee S Biomed Pharmacother; 2018 May; 101():211-218. PubMed ID: 29494958 [TBL] [Abstract][Full Text] [Related]
3. Compositional differences in gastrointestinal microbiota in prostate cancer patients treated with androgen axis-targeted therapies. Sfanos KS; Markowski MC; Peiffer LB; Ernst SE; White JR; Pienta KJ; Antonarakis ES; Ross AE Prostate Cancer Prostatic Dis; 2018 Nov; 21(4):539-548. PubMed ID: 29988102 [TBL] [Abstract][Full Text] [Related]
4. Abiraterone Acetate, in Combination with Apigenin, Attenuates the Survival of Human Castration-Sensitive Prostate Cancer Cells. Genc F; Atabey US; Serttas R; Erdogan S Anticancer Agents Med Chem; 2022; 22(18):3148-3156. PubMed ID: 35473536 [TBL] [Abstract][Full Text] [Related]
5. Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer. Rehman Y; Rosenberg JE Drug Des Devel Ther; 2012; 6():13-8. PubMed ID: 22291466 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of abiraterone acetate plus prednisolone in patients with early metastatic castration-resistant prostate cancer who failed first-line androgen-deprivation therapy: a single-arm, phase 4 study. Kobayashi K; Okuno N; Arai G; Nakatsu H; Maniwa A; Kamiya N; Satoh T; Kikukawa H; Nasu Y; Uemura H; Nakashima T; Mikami K; Iinuma M; Tanabe K; Furukawa J; Kobayashi H Jpn J Clin Oncol; 2021 Apr; 51(4):544-551. PubMed ID: 33324967 [TBL] [Abstract][Full Text] [Related]
7. Redirecting abiraterone metabolism to fine-tune prostate cancer anti-androgen therapy. Li Z; Alyamani M; Li J; Rogacki K; Abazeed M; Upadhyay SK; Balk SP; Taplin ME; Auchus RJ; Sharifi N Nature; 2016 May; 533(7604):547-51. PubMed ID: 27225130 [TBL] [Abstract][Full Text] [Related]
8. Abiraterone acetate to treat metastatic castration-resistant prostate cancer in combination with prednisone. Duarte C; Jimeno A; Kessler ER Drugs Today (Barc); 2019 Jan; 55(1):5-15. PubMed ID: 30740608 [TBL] [Abstract][Full Text] [Related]
9. Identification of mechanisms of resistance to treatment with abiraterone acetate or enzalutamide in patients with castration-resistant prostate cancer (CRPC). Pal SK; Patel J; He M; Foulk B; Kraft K; Smirnov DA; Twardowski P; Kortylewski M; Bhargava V; Jones JO Cancer; 2018 Mar; 124(6):1216-1224. PubMed ID: 29266182 [TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics, pharmacodynamics and clinical efficacy of abiraterone acetate for treating metastatic castration-resistant prostate cancer. Han CS; Patel R; Kim IY Expert Opin Drug Metab Toxicol; 2015 Jun; 11(6):967-75. PubMed ID: 25936418 [TBL] [Abstract][Full Text] [Related]
11. How I do it: Prescribing abiraterone acetate for metastatic castration resistant prostate cancer. Wang Y; Dason S; Shayegan B Can J Urol; 2016 Aug; 23(4):8388-94. PubMed ID: 27544566 [TBL] [Abstract][Full Text] [Related]
12. Enzalutamide in Combination with Abiraterone Acetate in Bone Metastatic Castration-resistant Prostate Cancer Patients. Efstathiou E; Titus M; Wen S; Troncoso P; Hoang A; Corn P; Prokhorova I; Araujo J; Dmuchowski C; Melhem-Bertrandt A; Patil S; Logothetis CJ Eur Urol Oncol; 2020 Feb; 3(1):119-127. PubMed ID: 31412017 [TBL] [Abstract][Full Text] [Related]
13. Commensal bacteria promote endocrine resistance in prostate cancer through androgen biosynthesis. Pernigoni N; Zagato E; Calcinotto A; Troiani M; Mestre RP; Calì B; Attanasio G; Troisi J; Minini M; Mosole S; Revandkar A; Pasquini E; Elia AR; Bossi D; Rinaldi A; Rescigno P; Flohr P; Hunt J; Neeb A; Buroni L; Guo C; Welti J; Ferrari M; Grioni M; Gauthier J; Gharaibeh RZ; Palmisano A; Lucchini GM; D'Antonio E; Merler S; Bolis M; Grassi F; Esposito A; Bellone M; Briganti A; Rescigno M; Theurillat JP; Jobin C; Gillessen S; de Bono J; Alimonti A Science; 2021 Oct; 374(6564):216-224. PubMed ID: 34618582 [TBL] [Abstract][Full Text] [Related]
14. Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial. Chi KN; Protheroe A; Rodríguez-Antolín A; Facchini G; Suttman H; Matsubara N; Ye Z; Keam B; Damião R; Li T; McQuarrie K; Jia B; De Porre P; Martin J; Todd MB; Fizazi K Lancet Oncol; 2018 Feb; 19(2):194-206. PubMed ID: 29326030 [TBL] [Abstract][Full Text] [Related]
15. The importance of targeting intracrinology in prostate cancer management. Hamid ARAH; Tendi W; Sesari SS; Mochtar CA; Umbas R; Verhaegh G; Schalken JA World J Urol; 2019 May; 37(5):751-757. PubMed ID: 30350016 [TBL] [Abstract][Full Text] [Related]
16. Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study. Saad F; Efstathiou E; Attard G; Flaig TW; Franke F; Goodman OB; Oudard S; Steuber T; Suzuki H; Wu D; Yeruva K; De Porre P; Brookman-May S; Li S; Li J; Thomas S; Bevans KB; Mundle SD; McCarthy SA; Rathkopf DE; Lancet Oncol; 2021 Nov; 22(11):1541-1559. PubMed ID: 34600602 [TBL] [Abstract][Full Text] [Related]
17. An up-to-date evaluation of abiraterone for the treatment of prostate cancer. Shpilsky J; Stevens J; Bubley G Expert Opin Pharmacother; 2021 Jul; 22(10):1227-1234. PubMed ID: 33856289 [No Abstract] [Full Text] [Related]
18. [Mechanisms of resistance to CYP17A1 inhibitors in castrate resistant prostate cancer]. Ripert T; Crouzet S; Ploussard G; De La Taille A; Robert G Prog Urol; 2013 Oct; 23 Suppl 1():S16-22. PubMed ID: 24314735 [TBL] [Abstract][Full Text] [Related]
19. Clinical Outcomes from Androgen Signaling-directed Therapy after Treatment with Abiraterone Acetate and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. Smith MR; Saad F; Rathkopf DE; Mulders PFA; de Bono JS; Small EJ; Shore ND; Fizazi K; Kheoh T; Li J; De Porre P; Todd MB; Yu MK; Ryan CJ Eur Urol; 2017 Jul; 72(1):10-13. PubMed ID: 28314611 [TBL] [Abstract][Full Text] [Related]
20. PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate. Ferraldeschi R; Nava Rodrigues D; Riisnaes R; Miranda S; Figueiredo I; Rescigno P; Ravi P; Pezaro C; Omlin A; Lorente D; Zafeiriou Z; Mateo J; Altavilla A; Sideris S; Bianchini D; Grist E; Thway K; Perez Lopez R; Tunariu N; Parker C; Dearnaley D; Reid A; Attard G; de Bono J Eur Urol; 2015 Apr; 67(4):795-802. PubMed ID: 25454616 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]